Drug Approval | June 11, 2026
AstraZeneca gets CDSCO nod for Trastuzumab Deruxtecan plus Pertuzumab
Approval expands treatment options for patients with unresectable or metastatic HER2-positive breast cancer
Approval expands treatment options for patients with unresectable or metastatic HER2-positive breast cancer
First-in-class topical androgen receptor inhibitor marks Glenmark’s first New Chemical Entity (NCE) launch in Europe
The validation confirms the submission is complete, clearing the way for the EMA’s centralized review process to formally evaluate the therapy
The campaign aims to raise awareness of a condition that affects an estimated 24 million adults in the US, many of whom remain undiagnosed
The Prayagraj lab is designed to handle both routine and specialised testing
Company may qualify for 180-day generic exclusivity as sole first applicant for Bayer’s Vitrakvi capsules in the U.S.
Deal brings late-stage lung cancer candidates zidesamtinib and neladalkib into GSK’s portfolio
The company gets access to Lonza’s clinically validated SYNtecan linker-payload platform as it prepares an IND filing for its acute myeloid leukemia therapy in 2027
The acquisition reflects Johnson & Johnson’s push to strengthen its position in antibody engineering and next-generation oncology modalities
The move makes EBGLYSS the only therapy offering as few as six maintenance injections per year
Subscribe To Our Newsletter & Stay Updated
